Results of a Phase 1, Open-label, Single-dose, Parallel-group Study of Rimegepant 75 mg in Subjects with Hepatic Impairment (2126)
Ivans A, Stringfellow J, Coric V, Croop R. Results of a Phase 1, Open-label, Single-dose, Parallel-group Study of Rimegepant 75 mg in Subjects with Hepatic Impairment (2126). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.2126.Peer-Reviewed Original ResearchRimegepant 75 mg Provides Early and Sustained Relief of Migraine With a Single Dose: Results from 3 Phase 3 Clinical Trials (2366)
Pavlovic J, Dodick D, Friedman D, Tepper S, Newman L, Lipton R, Stock E, Thiry A, Conway C, Jensen C, Morris B, Coric V, Croop R. Rimegepant 75 mg Provides Early and Sustained Relief of Migraine With a Single Dose: Results from 3 Phase 3 Clinical Trials (2366). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.2366.Peer-Reviewed Original Research